A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study

Background: The pathophysiological pathways resulting in Late Stent Thrombosis (LST) remain uncertain. Findings from animal studies indicate a role of the intrinsic coagulation pathway in arterial thrombus formation, while clinical studies support an association with ischemic cardiovascular disease. It is currently unknown whether differences in the state of the contact system might contribute to the risk of LST or Very Late Stent Thrombosis (VLST). We assessed the relation between levels of several components involved in the contact system and a history of LST and VLST, termed (V)LST in a cohort of 20 patients as compared to a matched control group treated with PCI. Methods and Results: Activated factor XII (FXIIa), FXII zymogen (FXII), FXIIa-C1-esterase inhibitor (C1-inhibitor), Kallikrein-C1-inhibitor, FXIa-C1-inhibitor and FXIa-α1-antitrypsin (AT-inhibitor) complexes were measured by Enzymelinked immunosorbent assy (ELISA) methodology. Cases and controls showed similar distributions in sex, age, baseline medications and stent type. Patients with a history of (V)LST had a significantly greater stent burden and a higher number of previous myocardial infarctions than the control patients. There were no significant between-group differences in the plasma levels of the components of the contact system. Conclusion: In a cohort of patients with a history of (V)LST, we did not observe differences in the activation state of the intrinsic coagulation system as compared to patients with a history of percutaneous coronary intervention without

[1]  H. Staines,et al.  Activated factor XII type A predicts long‐term mortality in patients admitted with chest pain 1 , 2009, Journal of thrombosis and haemostasis : JTH.

[2]  B. Boehm,et al.  Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk , 2008, Journal of thrombosis and haemostasis : JTH.

[3]  C. Hack,et al.  The plasma kallikrein–kinin system and risk of cardiovascular disease in men , 2007, Journal of thrombosis and haemostasis : JTH.

[4]  R. Jaffe,et al.  Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. , 2007, Journal of the American College of Cardiology.

[5]  B. Jilma,et al.  Evidence of a U‐shaped association between factor XII activity and overall survival , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  StéphaneCook,et al.  Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation , 2007 .

[7]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[8]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[9]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[10]  Frits R Rosendaal,et al.  Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. , 2006, Blood.

[11]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[12]  T. Melberg,et al.  Late complications following the deployment of drug eluting stents. , 2006, International journal of cardiology.

[13]  K. Kent,et al.  Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents , 2006, Circulation.

[14]  T. Renné,et al.  Defective thrombus formation in mice lacking coagulation factor XII , 2005, The Journal of experimental medicine.

[15]  F. Eberli,et al.  Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. , 2005, European heart journal.

[16]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[17]  H. Fagertun,et al.  Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. , 2004, American heart journal.

[18]  Jacqueline P Mitchell,et al.  Comparison of Novel Hemostatic Factors and Conventional Risk Factors for Prediction of Coronary Heart Disease , 2000, Circulation.

[19]  G. Miller,et al.  Epidemiological and Genetic Associations of Activated Factor XII Concentration With Factor VII Activity, Fibrinopeptide A Concentration, and Risk of Coronary Heart Disease in Men , 2000, Circulation.

[20]  R. Colman,et al.  Thrombin and Human Plasma Kallikrein Inhibition during Simulated Extracorporeal Circulation Block Platelet and Neutrophil Activation , 1998, Thrombosis and Haemostasis.

[21]  J. Cooper,et al.  Risk of coronary heart disease and activation of factor XII in middle-aged men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Z. Toossi,et al.  Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Colman,et al.  Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. , 1986, Blood.

[24]  J. Dunn,et al.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. , 1983, The Journal of clinical investigation.

[25]  K. Fujikawa,et al.  Mechanism of activation of bovine factor XI by factor XII and factor XIIa. , 1980, Biochemistry.

[26]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1971, The Journal of experimental medicine.

[27]  R. van Oerle,et al.  A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. , 2010, Thrombosis journal.

[28]  G. Panic,et al.  [Late stent thrombosis]. , 2009, Medicinski pregled.

[29]  P. Keeling,et al.  The dinoflagellates Durinskia baltica and Kryptoperidinium foliaceum retain functionally overlapping mitochondria from two evolutionarily distinct lineages , 2007, BMC Evolutionary Biology.

[30]  G. Miller,et al.  A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor. , 2000, Thrombosis and haemostasis.

[31]  A. Carter,et al.  Levels of Activated FXII in Survivors of Myocardial Infarction – Association with Circulating Risk Factors and Extent of Coronary Artery Disease , 1998, Thrombosis and Haemostasis.

[32]  G. Murano The “Hageman” connection: Interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation , 1978, American journal of hematology.

[33]  R. Colman,et al.  Activation of bovine factor VII by hageman factor fragments. , 1977, Blood.